期刊
BULLETIN DU CANCER
卷 109, 期 4, 页码 387-389出版社
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.bulcan.2022.01.004
关键词
Anti-PD-1; Immunotherapy; Pembrolizumab; Triple-negative breast neoplasms